Publications

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome

A new publication in Blood Cancer Journal August 2019

Primary author: Jeffrey R. Sawyer, Ph.D. Some multiple myeloma patients develop adverse chromosome abnormalities such as increases of the long arm of chromosome arm 1. The longer arm of the two sections of chromosome 1 is referred to as chromosome 1q. Sawyer describes a new syndrome in myeloma called “Jumping 1q Syndrome.” These patients

on outcome

diagnosed multiple myeloma. Daratumumab have instability of the genetic material in their myeloma cells and can develop multiple copies of 1 q, which ‘jump’ to other chromosomes with which they fuse. This way patients can have as many as five or more copies of 1q in their myeloma cells. The development of the chromosome 1q abnormalities can confer resistance to therapy. It is important to recognize these patients since they may require new

Daratumumab in high risk relapsed/refractory multiple myeloma patients: Adverse effect of 1q21 gain/amplification and GEP70 status

approaches to treatment.

A new publication in British Journal of recognizes a molecule called CD38 on Haematology myeloma cells and activates the immune Daratumumab in high-risk relapsed/refractory system to kill myeloma. Human cells have 23 multiple myeloma patients: adverse effect pairs of chromosomes containing the genetic of chromosome 1q21 gain/amplification and material. The Myeloma Center was one of the GEP70 status on outcome. first to report that the presence of multiple copies of the long arm of chromosome 1 in Mohan M, Weinhold N, Schinke C, the myeloma cells is associated with worse Thanedrarajan S, Rasche L, Sawyer JR, Tian E, outcome. Zangari and colleagues found that van Rhee F, Zangari M. Br J Haematol. 2019 patients with relapsed myeloma who have Dec 9. doi: 10.1111/bjh.16292. [Epub ahead of multiple copies of chromosome 1 also respond print] less well to treatment with daratumumab. The Daratumumab is a monoclonal antibody daratumumab treatment to those patients who used for the treatment of relapsed and newly are most likely to derive benefit. results of this study will allow for targeting